THE DEFIFRANCE REGISTRY STUDY: EFFECTIVENESS AND SAFETY OF DEFIBROTIDE IN PATIENTS WITH VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME FOLLOWING CHEMOTHERAPY
I Yakoub-Aghaa, D Blaiseb, J Dallec, S Labopin Md, Chantepiee, J Pongf, N Dronamrajug, F Ducheneh, M Mohtyd
a Centre Hospitalier Universitaire [CHU] de Lille, Université Lille, Institut national de la santé et de la recherche médicale [INSERM U1286], Lille, France
b Institut Paoli-Calmettes, Aix Marseille Univ, Centre national de la recherche scientifique [CNRS], INSERM, Cancer Research Center of Marseille [CRCMMarseille, France
c Hôpital Robert-Debré, Groupes hospitalo-universitaires [GHU] de l'Assistance publique – hôpitaux de Paris [APHP] Nord and Université of Paris, Paris, France
d Hôpital St Antoine, Sorbonne University, INSERM Unite mixté de recherche scientifique [UMRs] Paris, France
e Institut d'Hématologie de Basse Normandie, Caen, France
f Jazz Pharmaceuticals, Oxford, United Kingdom
g Jazz Pharmaceuticals, Philadelphia, United States
h Jazz Pharmaceuticals, Lyon, France
Lido
1425
Vezesque se leu este artigo
536
Total PDF
889
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 15 | 9 | 24 |
| 2025 5 | 34 | 14 | 48 |
| 2025 4 | 28 | 12 | 40 |
| 2025 3 | 48 | 10 | 58 |
| 2025 2 | 57 | 13 | 70 |
| 2025 1 | 42 | 15 | 57 |
| 2024 12 | 25 | 13 | 38 |
| 2024 11 | 31 | 24 | 55 |
| 2024 10 | 17 | 21 | 38 |
| 2024 9 | 24 | 19 | 43 |
| 2024 8 | 26 | 21 | 47 |
| 2024 7 | 23 | 21 | 44 |
| 2024 6 | 28 | 28 | 56 |
| 2024 5 | 42 | 22 | 64 |
| 2024 4 | 28 | 19 | 47 |
| 2024 3 | 47 | 19 | 66 |
| 2024 2 | 55 | 16 | 71 |
| 2024 1 | 50 | 19 | 69 |
| 2023 12 | 51 | 21 | 72 |
| 2023 11 | 39 | 18 | 57 |
| 2023 10 | 44 | 22 | 66 |
| 2023 9 | 38 | 29 | 67 |
| 2023 8 | 8 | 26 | 34 |
| 2023 7 | 10 | 16 | 26 |
| 2023 6 | 13 | 19 | 32 |
| 2023 5 | 17 | 3 | 20 |
| 2023 4 | 18 | 13 | 31 |
| 2023 3 | 5 | 8 | 13 |
| 2023 2 | 6 | 12 | 18 |
| 2023 1 | 5 | 5 | 10 |
| 2022 12 | 8 | 17 | 25 |
| 2022 11 | 5 | 8 | 13 |
| 2022 10 | 2 | 4 | 6 |
Mostrar tudo
